HDAC9 and extranodal nasal NK/T cell lymphoma: On the other hand, the histone deacetylase (HDAC) inhibitors belinostat and romidepsin are recommended in the National Comprehensive Cancer Network guidelines (version 2.2022) for R/R extranodal NKTCL, but the strength of evidence is weak and should be used in certain circumstances.